Literature DB >> 25640063

The potential of CD44 as a diagnostic and prognostic tool in oral cancer.

Helena Emich1, David Chapireau2, Iain Hutchison3, Ian Mackenzie1.   

Abstract

The CD44 family of molecules exists as a wide range of isoforms ubiquitously expressed on the surface of mammalian cells. The variation in patterns of CD44 expression on cancer cells has been widely studied in relation to their behaviour, and further interest has recently arisen in CD44 as a marker of the subfraction tumour cells acting as cancer stem cells in several types of tumours. This review focuses on the patterns of CD44 expression on the stem cell fraction of oral squamous cell carcinoma and on the relationship of detectably different patterns of CD44 expression to the behaviour of tumours.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CD44; cancer stem cells; oral cancer; prognosis

Mesh:

Substances:

Year:  2015        PMID: 25640063     DOI: 10.1111/jop.12308

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  9 in total

1.  Inferring novel genes related to oral cancer with a network embedding method and one-class learning algorithms.

Authors:  Lei Chen; Yu-Hang Zhang; Guohua Huang; Xiaoyong Pan; Tao Huang; Yu-Dong Cai
Journal:  Gene Ther       Date:  2019-08-27       Impact factor: 5.250

2.  CD44 Mediates Oral Squamous Cell Carcinoma-Promoting Activity of MRE11 via AKT Signaling.

Authors:  Shyng-Shiou F Yuan; Amos C Hung; Ching-Wei Hsu; Ting-Hsun Lan; Chang-Wei Su; Tsung-Chen Chi; Yu-Chiuan Chang; Yuk-Kwan Chen; Yen-Yun Wang
Journal:  J Pers Med       Date:  2022-05-21

3.  Cancer-associated fibroblasts secrete hypoxia-induced serglycin to promote head and neck squamous cell carcinoma tumor cell growth in vitro and in vivo by activating the Wnt/β-catenin pathway.

Authors:  Junqi Xie; Xiaofeng Qi; Yufeng Wang; Xiteng Yin; Wenguang Xu; Shengwei Han; Yu Cai; Wei Han
Journal:  Cell Oncol (Dordr)       Date:  2021-03-02       Impact factor: 6.730

4.  The clinicopathological and prognostic value of CD44 expression in bladder cancer: a study based on meta-analysis and TCGA data.

Authors:  Yu Hu; Yongrui Zhang; Jialin Gao; Xin Lian; Yuantao Wang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

Review 5.  The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview.

Authors:  Giovanni Barillari; Ombretta Melaiu; Marco Gargari; Silvia Pomella; Roberto Bei; Vincenzo Campanella
Journal:  Int J Mol Sci       Date:  2022-07-28       Impact factor: 6.208

Review 6.  Prognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Xintao Li; Xin Ma; Luyao Chen; Liangyou Gu; Yu Zhang; Fan Zhang; Yun Ouyang; Yu Gao; Qingbo Huang; Xu Zhang
Journal:  Sci Rep       Date:  2015-08-19       Impact factor: 4.379

7.  Epithelial-Mesenchymal Transition during Metastasis of HPV-Negative Pharyngeal Squamous Cell Carcinoma.

Authors:  Friedrich Ihler; Ronja Gratz; Hendrik A Wolff; Bernhard G Weiss; Mattis Bertlich; Julia Kitz; Gabriela Salinas; Margret Rave-Fränk; Martin Canis
Journal:  Biomed Res Int       Date:  2018-03-06       Impact factor: 3.411

8.  Selectin Binding Sites Are Involved in Cell Adhesive Properties of Head and Neck Squamous Cell Carcinoma.

Authors:  Ursula Valentiner; Jillian Knips; Ralph Pries; Till Clauditz; Adrian Münscher; Guido Sauter; Barbara Wollenberg; Udo Schumacher
Journal:  Cancers (Basel)       Date:  2019-10-28       Impact factor: 6.639

9.  CD44, γ-H2AX, and p-ATM Expressions in Short-Term Ex Vivo Culture of Tumour Slices Predict the Treatment Response in Patients with Oral Squamous Cell Carcinoma.

Authors:  Pierre Philouze; Arnaud Gauthier; Alexandra Lauret; Céline Malesys; Giovanna Muggiolu; Sylvie Sauvaigo; Antoine Galmiche; Philippe Ceruse; Gersende Alphonse; Anne-Sophie Wozny; Claire Rodriguez-Lafrasse
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.